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Copy number variationsGenetic alterations of the short arm of chromosome 9 are frequent in acute lymphoblastic leukemia. We
performed targeted sequencing of 9p region in 35 adolescent and adult acute lymphoblastic leukemia pa-
tients and sought to investigate the sensitivity of detecting copy number alterations in comparison with
array comparative genomic hybridization (aCGH), and besides, to detect novel genetic anomalies. We
found a high concordance of copy number variations (CNVs) as detected by next generation sequencing
(NGS) and aCGH. By both methodologies, the recurrent deletion at CDKN2A/B locus was identiﬁed, whereas
NGS revealed additional, small regions of CNVs, seen more frequently in adult patients, while aCGH was bet-
ter at detecting larger CNVs. Also, by NGS, we detected novel structural variations, novel SNVs and small
insertion/deletion variants. Our results show that NGS, in addition to detecting mutations and other genetic
aberrations, can be used to study CNVs.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
In acute lymphoblastic leukemia (ALL), one of the most recurrently
altered chromosomal regions is 9p containing numerous neoplasia-
associated genes such as JAK2 at 9p24.1, PAX5 at 9p13.2, as well as
CDKN2A, CDKN2B, MTAP, IFN genes, MLLT3, and PTPLAD2 at 9p21.3.
These genes have been shown to be affected in ALL by homozygous
and heterozygous deletions, loss of heterozygosity (LOH), mutations,
promoter hypermethylation, and translocations [1–7]. Various mecha-
nisms associated with these 9p alterations, such as the role of fragile
sites, miRNAs and methylation clusters, and also sequence homology
with antigen receptor genes in causal connection with rearrangement
formation, have been widely studied [3–5]. The methods used for the
previous studies include mainly karyotyping and ﬂuorescence in situ
hybridization (FISH) for fusion genes, array comparative genomic hy-
bridization (aCGH) and SNP arrays for copy number changes, and direct
sequencing and PCR for gene mutations.
Next generation sequencing (NGS) enables to study not only
gene mutations but also copy number variations (CNVs), structural
rearrangements and fusion genes in one experiment. Hence,tment of Pathology, PO Box 21
land. Fax: +358 9 191 26675.
ila).
rights reserved.utilizing a series of 35 patients with acute lymphoblastic leukemia,
previously studied for copy number alterations by array compara-
tive genomic hybridization (aCGH), we performed genomic analy-
sis of the 9p region in these patients by 9p-targeted resequencing.
Our principal aim was to compare the results of copy number changes
by the twomethods, and besides, to reveal novel copy number changes,
gene mutations, fusions, and their frequencies in ALL.
2. Results
2.1. Copy number variations (CNV) by NGS
CNV analysis of 35 ALL cases showed copy number losses in 26
patients in the 9p21.3 region. The size of the deleted region varied
considerably between the samples, ranging from smallest 0.3 kb
(exon 2 of CDKN2A) in ALL-17 and ALL-34, to the entire target region.
The most recurrent loss within 9p21.3, seen in 26 cases, was a 34 kb,
(chr.9:21,970,856-22,005,115) region (Fig. 1), harboring the CDKN2A/B
gene. Of the 26 patients, 22 had homozygous deletions within this re-
gion (Table 1).
2.1.1. Comparison of NGS and aCGH data for CNV detection
The results observed with NGS and aCGH are presented in Table 1.
In addition to the commonlydeleted9p21.3 region seenbybothmethods,
Fig. 1. Copy number variations in 9p detected by targeted NGS sequencing in adolescent (ALL 2-33) and adult (ALL 34-46) ALL patients. Regions with frequent CNVs detected by
NGS are indicated by black bars marked R1 (chr 9:5111498–5113815), R2 (chr 9:19102475–19121201), R3 (chr 9:33288771–33524540), R4 (chr 9:36881901–37036509). Black
vertical line along the ideogram shows the region studied by NGS. CNV shown are only from the target regions included in NGS. DNA sample from ALL-4 was used as reference
for CNV by NGS. The colored region corresponds to CNVs detected with NGS and that marked with pattern correspond to that detected with aCGH. Region with color and no pattern
correspond to CNV detected only by NGS and the region marked only with pattern and no color correspond to CNV seen only with aCGH.
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However, while NGS was more sensitive in detecting smaller deletions
it was unable to detect large/whole-arm deletions, which were, in this
study, determined on the basis of the aCGH data, as described in
Section 5.4.2.1.2. CDKN2A/B locus
By both NGS and aCGH methods, 26 out of a total of 35 (74%)
showed similar results of copy number analysis at the 9p21.3 regionTable 1
Comparison of 9p region for CNV and loss of CDKN2A/B as seen with aCGH and NGS.
No of cases Region of 9p loss Loss of
CDKN2A/B
aCGH NGS aCGH NGS
Similar in both aCGH and NGS
ALL-2, 5, 7, 10, 11, 18,
25, 29, 31, 32, 33
Region of loss at 9p21 Region of loss at 9p21 hmz hmz
ALL-20 Region of loss at 9p21 Region of loss at 9p21 htz htz
ALL-3, 28, 40, 44, 45 9p loss target region loss hmz hmz
ALL-6 9p gain target region gain
ALL-4,* 8, 9, 36, 38,
41, 42
No imbalance at 9p No imbalance at 9p
ALL-35, 46 Region of loss at 9p21 Region of loss at 9p21 htz hmz
Difference in size of deletion
ALL-16,37 9p loss Region of loss at 9p21 hmz htz
ALL-27, 43 Loss at 9p21-9p13 Region of loss at 9p21 hmz hmz
ALL-12 Loss at 9p21-9p13 No loss at 9p21-9p13 htz
Loss detected only with NGS
ALL-17,34 No imbalance at 9p Region of loss at 9p21 hmz
ALL-39 No imbalance at 9p Region of loss at 9p21 htz
hmz, homozygous; htz, heterozygous.
*ALL-4 was used as reference for CNV analysis by NGS.(Table 1). Of these concordant cases, 6 patients had normal copy num-
ber while one patient had gain of 9p. In the remaining 19 patients, the
deletion size of CDKN2A/B was similar by both methods, albeit two of
these patients differed regarding the homozygous/heterozygous status
of CDKN2A/B deletion. The results of 5 patients with large part of chro-
mosome 9p deleted in aCGH data, were inconsistent between aCGH
and NGS. On the other hand, in 3 patient, NGS analysis detected a
small deletion (b50 kb) that was not seen with aCGH.
2.1.3. Recurrent CNVs seen only by NGS and mainly in adult ALL
Besides the frequently deleted CDKN2A/B region, there were
other less recurrent CNVs, seen more frequently in adult ALL
patients and only with NGS. The prominent regions included:
chr.9:5,111,498-5,113,815 bp (R1, Fig. 1) with loss within this re-
gion seen in 8 patients (5 adult and 3 adolescent ALL) and a gain
in 2 patients; loss within chr.9:19,102,475-19,121,201 region (R2,
Fig. 1) in 10 patients (4 adolescent and 6 adult); loss within
chr.9:33,288,771-33,524,540 (R3, Fig. 1) seen in 12 (2 adolescent; 10
adult ALL); a loss within chr.9:36,881901-37,036,509 region (R4, Fig. 1)
seen in 9 (3 adolescent, 6 adult ALL) and a gain in 3 patients.
2.2. Single nucleotide variations (SNVs)
Tumor DNA from patients showed, on an average, 1340 variants
within the target region on 9p for each patient. SNVs observed in all 35
ALL patients were sorted, and those SNVs that were non-coding or
resulted in synonymous change or were recorded in dbSNP 135 were
ﬁltered out. Finally, 30 novel non-synonymous SNVs were detected
(Table 2). While most of these variations were seen in individual pa-
tients, there were 4 recurrent SNVs seen in FAM214B, PIGO, PRSS3, and
RUSC2 (present in 2 patients). Overall, the genes, ADAMTSL1, PIGO or
RUSC2 were affected in at least three patients by non-synonymous
SNVs.
Table 2
Novel non-synonymous variations along with copy number variation observed at these
loci in ALL patients.
Patient Position on chromosome 9 CNV Gene Amino acid change
ALL-45 g.5231711 G>A Loss INSL4 Arg(63)His
ALL-38 g.5549463A>C N PDCD1LG2 Thr(164)Pro
ALL-25 g.12775965 G>T N LURAP1L Gly(84)Val
ALL-11 g.14792848 G>A N FREM1 Arg(1292)Cys
ALL-32 g.15307246C>G N TTC39B Gly(26)Arg
ALL-7 g.18675880 T>C N ADAMTSL1 Tyr(371)His
ALL-40 g.18775808 G>A Loss ADAMTSL1 Gly(822)Asp
ALL-5 g.18775844C>T N ADAMTSL1 Pro(834)Leu
ALL-43 g.21239667 G>T Loss IFNA14 Leu(90)Ile
ALL-27 g.26984513 G>A N IFT74 Val(141)Ile
ALL-8 g.33029927 T>C N DNAJA1 Tyr(119)His
ALL-36 g.33113553 T>A N B4GALT1 Met(366)Leu
ALL-46 g.33469243C>T N NOL6 Arg(275)His
ALL-3 g.33798543A>G Loss PRSS3 Lys(229)Glu
ALL-3 g.33798574 G>A* Loss PRSS3 Ser(239)Thr
ALL-40 g.33798574 G>A* Loss PRSS3 Ser(239)Thr
ALL-43 g.33986826 T>C N UBAP2 Glu(151)Gly
ALL-2 g.34372673 G>A N KIAA1161 Ala(90)Val
ALL-37 g.34521597C>G N ENHO Ala(33)Pro
ALL-39 g.34637393 G>T N SIGMAR1 Ser(59)Tyr
ALL-32 g.35091321 T>C N PIGO Ile(855)Val
ALL-3 g.35093527 T>C* Loss PIGO Asp(277)Gly
ALL-44 g.35093527 T>C* Loss PIGO Asp(277)Gly
ALL-34 g.35107658A>C* N FAM214B Val(205)Gly
ALL-43 g.35107658A>C* N FAM214B Val(205)Gly
ALL-45 g.35546739C>A Loss RUSC2 Pro(74)Gln
ALL-35 g.35547077A>C* N RUSC2 Thr(187)Pro
ALL-43 g.35547077A>C* N RUSC2 Thr(187)Pro
ALL-17 g.35555632C>A N RUSC2 Leu(864)Ile
ALL-34 g.35609323 G>T N TESK1 Ala(489)Ser
ALL-42 g.35819211 T>C N FAM221B His(345)Arg
ALL-42 g.35819909C>A N FAM221B Leu(277)Phe
ALL-41 g.36121624 G>A N RECK Ser(878)Asn
ALL-28 g.37002702C>G Loss PAX5 Gly(183)Arg
CNV, copy number variation; N, normal copy number.
*variant present in two patients.
Table 3
Novel insertion/deletion (InDel) variants within coding region of genes on chromo-
some 9.
Indel Gene
1. g.5922623_5922625delGCA KIAA2026
2. g.6610286_6610287insA GLDC
3. g.33264393_33264410delGGGTCAACTCCTCGCTCC BAG1
4. g.33797928_33797929insCC PRSS3
5. g.34977582_34977584delCAG KIAA1045
6. g.35906348_35906350delCTG HRCT1
7. g.35906560_35906562delCCC HRCT1
8. g.36840628_36840635delGGGAGCCT PAX5
9. g.36882005_36882006insACCATGGGCAA PAX5
Table 4
Paired-end anomalies seen within 9p region showing small deletions, inversions and
translocations.
Position
Mb
Size
Mb
Breakpoint Type of
rearrangement
Genes No. of
patients
1. 9p:33,52
9q:66,49
ANKRD18B
(upstrream)
PTGER4P2-
CDK2AP2P2
(upstream)
Inversion
pericentric
8
2. 9p:33,52
9q: 99,98
ANKRD18B
(upstream)
C9orf174
Inversion
pericentric
13
3. 9p:21,47
9p:22,53
1.06 MIR31HG Inversion
paracentric
MIR31HG,
MTAP,
C9orf53,
CDKN2A,
CDKN2B-AS1,
DMRTA1
1
4. 9p:33,57
9p:38,57
5.0 ANKRD18B/
ANKRD18A
Inversion
paracentric
many, PAX5 2
5. 9p:37,03
9p:37,13
0.10 PAX5-ZCCHC7 Inversion
paracentric
PAX5,
NR_036592,
ZCCHC7
1
6. 9p: 21,98
9p: 22,00
0.03 CDKN2A/
CDKN2B-AS1
Deletion CDKN2A/2B 2
7. 9p: 33,52
9p:45,35
11.8 many, PAX5 Inversion
paracentric
many,PAX5 2
8. 9p:33,03
9p: 40,07
7.04 DNAJA1 Deletion many 1
9. 9p:19
7p
HAUS6-3′UTR Inter-chromosomal 3
10. 9p:35,07
16q
FANCG Inter-chromosomal 1
11. 9p:33,29
19p
NFX
(upstream)
NACC1-3′UTR
Inter-chromosomal 1
12. 9p:27,
0-Xq
IFT74-EDA Inter-chromosomal 1
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On average, 342 indel variants were observed in the target region of
each patient. Compared to SNVs there were very few indels detected in
the coding region of the genes and 9 novel non-synonymous indels
(not recorded in dbSNP135) were observed (Table 3). Majority of the
novel indels detected in ALL patients were in 3′-UTR of the genes. Seven
novel indels were seen in 5′-UTR region of genes, of which 4 were seen
in 5′-UTR of PAX5 gene. Four of the 9 novel indels lead to frameshift
change. Two novel frameshift indels were identiﬁed in PAX5 gene.
2.4. Structural rearrangements/paired-end anomalies
We found 12 different kinds of paired-end anomalies mapping
within the target region (Table 4). Two types of recurrent pericentric
inversions, with a common break-point at 33.52 Mb, located 1 kb up-
stream of ANKRD18B gene in our 9p target region were detected. The
othermate pair breakpointwas in 9q armeither at 66.49 Mb (8 patients)
or at 99.98 Mb (13 patients). Four paracentric inversions of 9p were
detected with the smallest insert size for paired-end anomaly of
100 kb and largest of 111.8 Mb. Three of these rearrangements in-
cluded PAX5 gene, while one of them had a breakpoint in MIR31HG
and included the often deleted CDKN2A gene. As for the 2 deletions
within 9p region, the smaller one, which was detected in two patients
(no. 6 in Table 4), was merely 30 kb and included only CDKN2A/
CDKN2B genes, whereas the other one was a deletion of 7 Mb (no. 8,
Table 4) involving many genes. Both deletions were veriﬁed by CNV
analysis of NGS and aCGH data.
In our study we detected four inter-chromosomal rearrangements
(Table 4), of which the most recurrent one was seen in 3 patients andinvolved chromosomes 9p and 7p, with a breakpoint in HAUS6 gene
on 9p. Other chromosomal rearrangements involved FANCG on 9p
and 16q (Fig. 2); 9p and NACC1 on 19p, as well as IFT74 on 9p and
EDA on Xq.3. Discussion
We have shown a high concordance of copy number variations
(CNVs) between next generation sequencing (NGS) and aCGH in ALL.
We used surplus frozen bonemarrow aspirates not needed for diagnostic
tests and the limited bonemarrow sample available for our study restrict-
ed us from undertaking further validation studies. We were neither able
to obtain normal bone marrow for reference sample for CNV analyses by
NGS. Thus we used patient (ALL 4) bone marrow sample as a reference.
As this bone marrow did not show any copy number alterations in chro-
mosome 9 by aCGH and had nomutation or structural rearrangement as
studied by NGS, we do not think that the selection of the reference had
inﬂuence on the CNV results.
Fig. 2. Detection of CNV and structural rearrangement involving chr.9p13.3 and chr16q23.1 in ALL-10 patient by NGS and aCGH. A. Copy number proﬁle of short arm of chromosome
9 as seen with NGS (represented as log2 ratio of ALL10/reference calculated from reads mapping to target regions and visualized with Agilent's Genomic bench). B. aCGH proﬁle
showing chr 9p in the same patient, with a loss at CDKN2A/B locus and another loss with a breakpoint (indicated by arrows) around chr.9:35076770. C. NGS data viewed in IGV
shows anonymously mapped pairs (yellow colored), detected by NGS with breakpoint in FANCG. D. aCGH plot showing similar breakpoint in FANCG. E. NGS data showing position
of the anonymously mapped pair at chr 16: 77136932–77137009 and Chr 16:77619921–77619998. F. aCGH results for the same coordinates on chr 16q23.1 showing two
breakpoints at exactly the same location as in NGS and depicting a loss of MON1B and ADAMTS18 genes within the region between the breakpoints, as seen with NGS.
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by NGS in all except one (ALL12) patient. However large deletions could
not be detected byNGS since the large deletions covered nearly the entire
sequenced region, making it challenging to control for within-sample
variation. The limitation of NGS in not being able to identify large dele-
tions is mainly becausewe studied only a small region of 32 Mb on chro-
mosome 9with a target capture of 1 Mb. CNVs larger than 13,85 Mb that
could not bedetected in our study, constitutednearly 43%of the target re-
gion. We anticipate that, in analogy to aCGH, inclusion of target regions
from other chromosomes in target design could be used to improve the
identiﬁcation of larger deletions with NGS.
On the other hand, NGS had a higher sensitivity of detecting small size
CNVs that could not be detected by aCGH (ALL17, ALL34 and ALL39,Table 1). For one of these patients (ALL17), we used 44 K array and for
the other two (ALL34 and ALL39), 244 K arrays. In two of these patients
(ALL17 and ALL34) NGS was able to detect single exon deletion of
CDKN2A. The single exon deletions detected by NGS includes exon 2 of
CDKN2A. This is the only coding region of this gene common to both,
p16INK4 (CDK inhibitor) andp14ARF (stabilizer of p53) proteins encoded
by this gene. Since the exon 2 is translated in different reading frames, de-
letion of exon 2 could thus lead to disruption of both the reading frames
and affect the function of both the genes. Even though these genes are
structurally and functionally very different, they both are important for
cell cycle G1 control by regulating CDK4 and p53 respectively.
In addition to the deletion of CDKN2A/B region, NGS revealed four
regions of CNV (Fig. 1). These were not detected by aCGH. Notably,
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poiesis. The ﬁrst region (R1) included part of the intronic region of JAK2
gene and a pseudogene. According to the Database of Genomic Varia-
tions (DGV), this region has been affected by a CNV (both loss/gain)
common in normal individuals. The second region (R2), included the
5′ UTR and ﬁrst exon of HAUS6 as well as a complete PLIN2 gene. A
large 4.56 MB region gain (Variation_52762), is reported in 2/2026
healthy individuals. The region (R3), which is centromeric to CDKN2A/B,
harbored NFX1, AQP7, AQP3, NOL6 and SUGT1P1 genes, with NFX1
being the most frequently deleted gene within this region. Copy
number gains and losses in genes AQP7, AQP3 and NOL6 are reported
in healthy individuals, especially more commonly in AQP7 while
there are no reports of CNV for NFX1 gene. As for the most centro-
meric region (R4), it harbored PAX5 and MIR4476 genes. Copy num-
ber loss (chr9:36438586–37407033) corresponding to R4 region is
reported in a single case from 1000 Genomes Project and somatic
rearrangements involving PAX5 are well known in ALL [7]. In our pa-
tients, PAX5 deletion was more frequently seen among adult patients
(46%) than in the group of adolescents (14%). Deletion of PAX5 has
been earlier reported in 29.7% of B-progenitor ALL [8], in 33% of
adolescent and adult ALL [9], as well as in 60% of adult and child-
hood ALL patients with 9p abnormality [6]. In our study the fre-
quency of CNV as whole was higher in adult than that in adolescent
ALL. However because of lack of normal DNA available from these pa-
tients, it is difﬁcult to know the acquired or germline nature of these
variations.
Since 9p is frequently deleted in ALL, SNVs in hemizygous condi-
tion could have deleterious effects. Notably, our NGS analyses re-
vealed several novel single nucleotide variations. However recurrent
mutations in CDKN2A were not detected, which is in accordance
with earlier studies [10]. In contrast, in PAX5, which is often mutated
in ALL, we found 3 novel frameshift indels/non-synonymous muta-
tions, in addition to novel indels in 5′-UTR region in 9 patients. Fur-
thermore, novel mutations were seen in RUSC2 (4 patients), PIGO
(3 patients) and in PRSS3 gene (3 patients). PIGO is involved in
GPI-anchor protein synthesis and is expressed in different kinds
of blood cells [11] and PRSS3 is implicated in cancer, speciﬁcally
in metastasis [12–15].
As for structural rearrangements involving 9p, they showed, in our
study, frequent pericentric inversions with breakpoint at 9p13.3 and
at either 9q13 or 9q22.33. The constitutional pericentric inversion
9p11–12 and 9q13–21.1 is one of the most common balanced struc-
tural chromosomal variations known to occur in 1–4% of the normal
population, and its predisposition to development of cancer and
haematological disorders has been indicated. Acquired somatic
form of 9p pericentric inversions with breakpoints at 9p13 and
9q12 is also reported in leukemia [16,17].
We detected in one patient structural rearrangement between
chromosomes 9 and 16 involved exons 6–7 of FANCG (Fig. 2). It is
worth mentioning that a higher incidence of leukemia is well known in
patients with germ line mutations in FANCG compared to other FANC
genes [18], but although mutations and indels are well known for this
gene, structural variation involving this gene is a new ﬁnding. Further-
more, our analysis, revealed in 3 patients a structural rearrangement be-
tween chromosomes 9 and 7, involvingHAUS6 on chromosome 9.HAUS6
is part of the augmin complex and is vital tomitotic spindle assembly and
cytokinesis in human cells [19,20]. A region of CNV involvingHAUS6was
also seen in the three patients.
Our in depth analysis of 9p genetic alterations with targeted next
generation sequencing highlights the 9p chromosomal fragility in ALL
patients. Due to the unavailability of normal DNA from these patients,
it is difﬁcult to conﬁrm constitutional vs. acquired nature of the genetic
abnormalities. However, the fact that the novel variations are nei-
ther seen in any latest builds of variation databases nor reported
in 1000 genomes data makes them more likely to be of acquired
nature.4. Conclusion
The comparison of CNV analysis of NGS and aCGH data showed sim-
ilar variation pattern in the most frequently deleted CDKN2A region in
our cohort of ALL patients. However, NGS had a higher sensitivity in
CNV detection of small local variations while aCGH detected larger
CNVsmore accurately. We conclude that in addition to detectingmuta-
tions and other genetic aberrations, targeted NGS provides high resolu-
tion tools to detect local copy number variations. Our ﬁndings pinpoint
novel genomic alterations in 9p and illustrate the high range of instabil-
ity of this chromosome area in ALL.
5. Materials and methods
5.1. Patients
Altogether, 35 patients with ALL, who were diagnosed and treated
at the Helsinki University Central Hospital, were included in the
targeted resequencing analysis of 9p region. Of the 35 ALL patients,
22 were adolescent and young adults (age 10–25 yrs; median 16 yrs)
with 14 males and 8 females, while the rest 13 were adult patients
(age over 25 yrs; median 49 yrs) including 9 males and 4 females.
The primary selection criteria of the patients, was, thus, the availability
of aCGH results and included those from whom DNA was left for NGS
analyses, comprising 25 patients with CNV and 10 patients without
any CNV for the 9p region. As regards ALL subtypes, our cohort was,
thus, not random but contained an excess of 9p deletion cases. The re-
sults of aCGH have been previously published elsewhere [3,7] and
aCGH data is available at www.CanGEM.org (details in supplemental
Table 2). This study was approved by the appropriate Institutional Re-
view Boards and the National Authority for Medico-legal Affairs.
5.2. aCGH
DNA was extracted from the bone marrow samples and used for
aCGH and NGS. ALL samples and reference DNA, pooled from periph-
eral blood of 4 healthy individuals, were differently labeled and hy-
bridized to the Agilent 44 K and 244 K CGH microarrays (Agilent
Technologies, Santa Clara, CA, USA) according to the manufacturer's
protocols. The arrays were scanned using the Agilent's microarray
scanner G2565AA (Agilent Technologies), while Agilent's Feature Ex-
traction software was used for image analysis and data was visualized
using the Genomic Workbench Standard Edition (version 5.0.14). The
most recurrently altered chromosomal region of 32 Mb was deﬁned
in 9p and selected for targeted sequencing.
5.3. Next generation sequencing
5.3.1. Target capture
Target regions with a total length of 1 Mb from a 32 Mb region of the
chromosome 9p were sequenced. For capture of target regions, baits
were customdesigned to capture all exons, 3′ and 5′ untranslated region
(UTR), and 1 kb upstream region of all genes within 9p24.2–9p13
(chr.9:4,848,246-37,036,509 in build GRCh37 of the human reference
genome). Custom designed baits were obtained from NimbleGen
(Roche NimbleGen, Inc., Madison, WI, USA). A total of 2358 target re-
gions, comprising of 191 protein coding andmiRNA geneswere included
in the capture (supplemental Table 1 shows the gene list).
5.3.2. Targeted sequencing
DNA, isolated from bone marrow cells was fragmented, ligated to
adapters and enriched for target regions using Roche NimbleGen's
in-solution target capture and enrichment protocol. Paired-end se-
quencing of the target-enriched librarieswas performed on the Illumina
Genome Analyser IIx and HISeq2000 sequencers (Illumina, Inc., San
Diego, CA, USA).
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Data obtained from sequencing was preprocessed with a variant-
calling pipeline (VCP) developed at the Finnish Institute of Molecular
Medicine (FIMM) [21]. Brieﬂy, VCP included ﬁltration of sequence
reads for quality, alignment of paired-end reads to the reference ge-
nome with the Burrows-Wheeler Aligner [22], duplicate fragment
removal by rmdup algorithm, variant calling and identiﬁcation of
anomalously mapped paired-reads. For variant calling, VCP utilized
SAMtools’ pileup [23]. SNV calling and read end anomaly calling, based
on FIMM's own developed algorithm, detection of indels with the Pindel
[24], visualization of anomalously mapping paired-end (PE) reads with
the Circos [25], were all included in the VCP. Results were visualized in
the Integrative Genomic Viewer (IGV) [26].
On an average, >93% of the target region had more than 20-fold
coverage for each patient.
5.4. Analysis of copy number variation
The reads mapping to target regions from the NGS were converted
into discrete copy number calls by using standard copy number prepro-
cessing techniques, including normalization, segmentation and calling
[27]. To control target sequence bias between different regions, the
comparison to reference sample was made in the raw data at the level
of individual bins. Analogous probe-level analysis has been shown to
improve comparability between multiple microarray platforms in the
context of gene expression microarray studies [28,29]. The selected ref-
erence sample for CNV analyses with NGS (sample 4) did not show any
copy number alterations in chromosome 9 by aCGH and had no muta-
tion or structural rearrangement as studied by NGS.
After the bin-level preprocessing, the logarithmized raw signal was
segmented using the CGHcall Bioconductor package [30]. Sincemeasure-
ments from other chromosomes were not available in our targeted NGS
study, whole-arm deletions or gains could not be determined solely on
the basis of NGS observations. The whole-arm alteration status (loss/
neutral/gain) was, therefore, ﬁrst determined for all samples based on
the aCGH data, and the median signal of the NGS segments was set ac-
cordingly to −1/0/1, corresponding to whole-arm deletion, no change,
and gain, respectively. Correction for the whole-arm alterations further
improved the comparability between NGS and aCGH regarding the sam-
ples with whole-arm alterations and facilitated the separation between
homo- and heterozygous alterations in the NGS data. Besides determin-
ing whole-arm alterations, the determination of local chromosomal
changes along the 9p arm was otherwise independent between the
NGS and aCGH data sets. The whole-arm alteration status for the NGS
analysis could alternatively be determined through the results of cytoge-
netic analysis, which wouldmake the NGS analysis completely indepen-
dent of aCGH measurements. Finally, the continuous copy number
signals from the segmentation step were discretized into ﬁve discrete
levels of copy number call, denoted by −2/−1/0/1/2 regarded as
homo- and heterozygous loss, unaltered region, and low and high
levels of chromosomal gain, respectively. The detection thresholds
were set such that homo- and heterozygous deletions correspond to
samples with b50% (b1/2) or b75% (b1.5/2) signal levels and low-
and high copy number gains correspond to >25% (>2.5/2) and >75%
(>3.5/2) increase in the signal level with respect to the reference, re-
spectively. The distinction between homo- and heterozygous deletions
depends on the selection of the cutoff threshold. We also veriﬁed that
the concordance between the NGS and aCGH copy number results
was not particularly sensitive to the selection of the cutoff (data not
shown).
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